San Diego-dependent Viking Therapeutics marked by itself as a significant competitor during the weight loss drug marketplace in February just after revealing promising info from a mid-phase trial of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when given as being a weekly injection and in March th